This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $2.94, representing a -6.67% change from its previous close.

A global restructuring at Massachusetts’ largest life sciences employer is set to result in local layoffs. $TAK ...

Kailera Therapeutics filed for a U.S. initial public offering on Friday, ​becoming the latest biotech company looking to ‌tap investor appetite as listings in the space gather momentum.

Jim Cramer reviewed Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) while breaking down 16 stocks for a market facing higher energy ...

The global pharmaceutical packaging market is entering a robust growth phase, driven by rising demand for safe, reliable, and patient-friendly drug packaging solutions across the pharmaceutical and ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its wholly owned subsidiary, ...

Merck MRK has been actively pursuing mergers and acquisitions (M&A) to strengthen its pipeline and sustain long-term growth, ...

While the accelerated approval unlocks only a small market opportunity for Rocket Pharmaceuticals, it will give the biotech a ...

Swiss drugmaker Novartis will buy California-based ‌biotech company Excellergy in a deal worth up to $2 billion, it said on ...

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than ...